C4 Therapeutics, Inc.

Ownership Transactions Reported by 23 Insiders

Symbol
CCCC on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
490 Arsenal Way, Suite 120, Watertown, Massachusetts

There are no Buy or Sell transactions made by insiders since 9/12/2023

C4 Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Alain J. Cohen Director $11.8M Apr 4, 2022
Glenn Dubin Director $6.58M Apr 1, 2024
Elena Prokupets Director $3.49M Sep 27, 2021
Andrew Hirsch President & CEO, Director $1.66M Feb 15, 2024
Kenneth Carl Anderson Director $1.54M Jul 1, 2024
Stewart Fisher Chief Scientific Officer $843K Mar 7, 2024
Kendra Adams Chief Financial Officer $536K Mar 7, 2024
Leonard Reyno Chief Medical Officer $459K Jul 10, 2024
Scott N. Boyle Chief Business Officer $342K Mar 7, 2024
Jolie Siegel Chief Legal Officer $341K Mar 7, 2024
Kelly Schick Chief People Officer $341K Mar 7, 2024
Lauren White Chief Financial Officer $213K Aug 30, 2023
Mark Mossler Chief Accounting Officer $160K Feb 14, 2024
Adam Crystal Chief Medical Officer $131K Jan 30, 2023
Donna Roy Grogan Director $128K Jul 1, 2024
Owen Hughes Director Jun 20, 2024
Bruce Downey Director Jun 20, 2024
Utpal Koppikar Director Jun 20, 2024
Marc A. Cohen Director Jun 22, 2022
Stephen Fawell Director Aug 29, 2024
Ronald Harold Wilfred Cooper Director Jun 7, 2024
Malcolm Salter Director Jun 20, 2024
Laura Bessen Director Jun 20, 2024

Recent Insider Transactions by Companies or Individuals for C4 Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.